» Articles » PMID: 9144461

Role of Fas Ligand (CD95L) in Immune Escape: the Tumor Cell Strikes Back

Overview
Journal J Immunol
Date 1997 May 15
PMID 9144461
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Several different tumor types have recently been shown to express functional Fas ligand (FasL), which may represent an additional mechanism of tumor escape. However, the in vivo significance of these findings in the context of potent adversaries such as activated CTL or NK cells remains to be fully established. The potential interactions between tumor cells and the host immune response are thus more complex than previously thought; their elucidation will benefit the rational design of cancer immunotherapy strategies.

Citing Articles

The crosstalk of CD8+ T cells and ferroptosis in cancer.

Lin Z, Zou S, Wen K Front Immunol. 2024; 14:1255443.

PMID: 38288118 PMC: 10822999. DOI: 10.3389/fimmu.2023.1255443.


MMP-7 marks severe pancreatic cancer and alters tumor cell signaling by proteolytic release of ectodomains.

Van Doren S Biochem Soc Trans. 2022; 50(2):839-851.

PMID: 35343563 PMC: 10443904. DOI: 10.1042/BST20210640.


Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.

Risso V, Lafont E, Le Gallo M Cell Death Dis. 2022; 13(3):248.

PMID: 35301281 PMC: 8931059. DOI: 10.1038/s41419-022-04688-x.


Cholest-4,6-Dien-3-One Promote Epithelial-To-Mesenchymal Transition (EMT) in Biliary Tree Stem/Progenitor Cell Cultures In Vitro.

Nevi L, Costantini D, Safarikia S, Di Matteo S, Melandro F, Berloco P Cells. 2019; 8(11).

PMID: 31731674 PMC: 6912632. DOI: 10.3390/cells8111443.


High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma.

Zhou Y, Wang X, Huang X, Li X, Cheng K, Yu H CNS Neurosci Ther. 2019; 26(3):309-318.

PMID: 31710183 PMC: 7081167. DOI: 10.1111/cns.13254.